Matrixyl 3000
What the Research Actually Shows
Human: 4 studies, 1 groups · Animal: 0 · In Vitro: 4
The dual-peptide successor that combines collagen building with collagen protection — and why two mechanisms may be better than one
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Matrixyl 3000 combines two peptides in one product. The first one (Pal-GHK) tells your skin cells to make more collagen. The second one (Pal-GQPR) tells your immune system to stop destroying the collagen you already have. In clinical studies, this two-pronged approach reduced wrinkle depth by 22 to 28 percent over 8 to 12 weeks — modestly better than the original Matrixyl's 18 to 20 percent. That is a real improvement, but still a modest one. Your skin will look gradually smoother and firmer over two to three months. It will not look ten years younger. The evidence comes almost entirely from the company that sells it, and the exact recipe (how much of each peptide) is a trade secret. Both of those things matter when evaluating the claims.
Matrixyl 3000 is Sederma's second-generation anti-aging peptide complex — the follow-up to the original Matrixyl (Pal-KTTKS) that earned the strongest clinical evidence of any cosmeceutical peptide. Where the original Matrixyl took a single approach (stimulate collagen synthesis via matrikine signaling), Matrixyl 3000 adds a second: suppress the inflammation and enzymatic degradation that destroy collagen from the other side. Build more and lose less — a strategy that any engineer would recognize as fundamentally superior to just building more.
The two components are Palmitoyl Tripeptide-1 (Pal-GHK), a copper-free version of the GHK tripeptide that signals fibroblasts to produce collagen, and Palmitoyl Tetrapeptide-7 (Pal-GQPR), an anti-inflammatory tetrapeptide that suppresses IL-6, TNF-α, and the collagen-digesting enzyme MMP-1. Both carry palmitoyl fatty acid chains for skin penetration. The proprietary ratio — how much of each peptide is in the blend — is not disclosed.
Sederma's own head-to-head data shows Matrixyl 3000 achieving 25% wrinkle reduction vs. 18% for single-peptide Matrixyl, a statistically significant difference. The evidence is entirely manufacturer-sponsored, but the dual-pathway logic is sound, and both components are separately supported by in vitro mechanistic data.
Like all topical peptides, delivery is the limiting factor. Microneedling — which bypasses the skin barrier to deliver peptides directly to the dermis — is particularly well-suited to Matrixyl 3000's dual-target biology. For protocols, see our [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/) guide.
In This Article
Quick Facts: Matrixyl 3000 at a Glance
Type
Dual-lipopeptide complex (tripeptide + tetrapeptide, both palmitoylated; proprietary ratio)
Also Known As
Pal-GHK + Pal-GQPR, INCI: Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7
Generic Name
Palmitoyl tripeptide-1 / palmitoyl tetrapeptide-7 complex
Brand Name
Matrixyl 3000 (Sederma/Lubrizol)
Molecular Weight
Pal-GHK: ~578 Da · Pal-GQPR: ~687 Da (both below typical MW cutoff for skin penetration)
Peptide Sequence
Pal-GHK: Pal-Gly-His-Lys-NH₂ · Pal-GQPR: Pal-Gly-Gln-Pro-Arg-NH₂
Endogenous Origin
GHK is a natural collagen-derived tripeptide (copper-free analog); GQPR is synthetic (immunoglobulin-inspired sequence)
Primary Molecular Function
Dual-pathway: matrikine collagen synthesis (Pal-GHK) + anti-inflammatory MMP-1 suppression (Pal-GQPR)
Active Fragment
Both peptides are individually active; Pal-GHK is the anabolic signal, Pal-GQPR is the catabolic inhibitor
Delivery Methods
Topical (primary) · Microneedling-enhanced topical (improved dual-peptide delivery to dermis) · Not used as injectable
Clinical Programs
No FDA drug development; Sederma-sponsored panels (N=20–40, 8–12 weeks), including head-to-head vs. single-peptide Matrixyl
Route
Topical application in cream or serum formulations (proprietary concentration)
FDA Status
Category A — both peptides accepted as cosmetic ingredients; proprietary blend ratio not disclosed
WADA Status
Not prohibited (cosmetic, minimal systemic absorption)
Community Interest
Premium anti-aging collagen stimulation — wrinkle reduction, skin firming, texture improvement; positioned as upgrade to original Matrixyl
Proprietary Limitation
Exact peptide ratio is a trade secret; limits independent reproducibility and mechanistic transparency
Evidence Tier
3 Pilot / Limited Human Data
Verdict
Reasonable Bet
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Matrixyl 3000? — Origins and Discovery
Pronunciation: MAY-tricks-il-THREE-thou-sand
Aging skin has two problems, and most anti-aging products address only one. The first problem is synthesis: as you age, your fibroblasts produce less collagen — roughly 1% less per year after age 20. The second problem is degradation: enzymes called matrix metalloproteinases (particularly MMP-1, or collagenase) actively chew through the collagen that remains, and chronic low-grade inflammation accelerates the process. The net effect — less being built, more being destroyed — is what you see in the mirror as wrinkles, sagging, and thinning skin.
The original Matrixyl (Pal-KTTKS) addressed the first problem: signal fibroblasts to build more collagen. Sederma's insight for Matrixyl 3000 was to address both simultaneously. Combine a collagen-synthesis signal (Pal-GHK, a matrikine tripeptide) with a collagen-protection agent (Pal-GQPR, an anti-inflammatory tetrapeptide that suppresses the enzymes and inflammation that destroy collagen). Build more and destroy less. The arithmetic is straightforward: net collagen = synthesis – degradation. Increase the numerator and decrease the denominator.
The GHK component has a natural pedigree. GHK (Gly-His-Lys) is a tripeptide released during collagen degradation that, like KTTKS, functions as a matrikine signal. It is also the backbone of GHK-Cu, the copper-binding peptide covered in Peptidings' [GHK-Cu article](/peptides/ghk-cu/) — one of the most extensively studied peptides in wound healing and tissue remodeling. Sederma's innovation was to remove the copper (which can cause irritation and oxidative stress with prolonged topical use) and add a palmitoyl anchor for skin penetration.
The GQPR component is entirely synthetic — designed to mimic an immunoglobulin-like anti-inflammatory sequence. Its specific receptor target has never been published in peer-reviewed literature, which is a transparency limitation.
PLAIN ENGLISH
Your skin ages in two ways: it makes less collagen, and it destroys more of what it has. Most anti-aging products try to address one of those problems. Matrixyl 3000 tries to address both — one peptide to boost production, another to slow destruction. The logic is sound. The evidence is promising but comes almost entirely from the company that sells it.
Mechanism of Action
Component 1: Pal-GHK — The Collagen Builder
Pal-GHK (Palmitoyl Tripeptide-1) is a lipidated version of GHK, a naturally occurring tripeptide released during collagen turnover. GHK is a matrikine — a fragment of extracellular matrix protein that signals cells to modify their behavior. In this case, the signal targets dermal fibroblasts:
Type I and III procollagen synthesis. GHK binds fibroblast surface receptors (incompletely characterized; likely integrins) and activates intracellular signaling cascades that upregulate collagen gene transcription. Sederma's in vitro data shows collagen synthesis stimulation comparable to GHK-Cu — the copper-containing version — without copper-associated irritation.
Fibronectin and GAG production. Beyond collagen, GHK signaling increases fibronectin (a structural glycoprotein that organizes the extracellular matrix) and glycosaminoglycans (including hyaluronic acid, which provides dermal hydration).
Component 2: Pal-GQPR — The Collagen Protector
Pal-GQPR (Palmitoyl Tetrapeptide-7) is a synthetic anti-inflammatory peptide designed to reduce the chronic, low-grade dermal inflammation — "inflammaging" — that accelerates collagen degradation:
IL-6 and TNF-α suppression. Pal-GQPR dose-dependently reduces pro-inflammatory cytokine production in stimulated fibroblasts and immune cells (Sederma in vitro, IC50 ~10 µM).
MMP-1 inhibition. MMP-1 (collagenase) is the primary enzyme responsible for degrading type I collagen in the dermis. By suppressing MMP-1 expression, Pal-GQPR directly protects existing collagen fibers from enzymatic destruction.
The Synergy Argument
Sederma's in vitro skin-equivalent studies show that combining Pal-GHK + Pal-GQPR produces 35–40% greater net collagen accumulation than either peptide alone. The proposed explanation: Pal-GHK drives collagen production upward while Pal-GQPR reduces collagen loss — the combined effect is multiplicative, not merely additive.
The clinical data supports this: Matrixyl 3000 achieved 25% wrinkle reduction vs. 18% for single-peptide Matrixyl in the only published head-to-head comparison.
Delivery and the Microneedling Advantage
Both components carry palmitoyl chains for skin penetration. Sederma's transepidermal flux studies show 3–5-fold improved penetration vs. unmodified peptides. However, dermal delivery at cosmetic concentrations remains the limiting factor.
Microneedling is especially compelling for Matrixyl 3000 because the compound has two distinct cellular targets: fibroblasts (for Pal-GHK) and inflammatory cells (for Pal-GQPR), both residing in the dermis. A 0.25–0.5 mm microneedling device delivers both peptides directly to this zone. See our [microneedling protocol guide](/guides/topical-peptides/#microneedling).
PLAIN ENGLISH
Matrixyl 3000 works two jobs at once. One peptide tells your skin to build new collagen. The other tells your immune system to stop inflaming and destroying the collagen you already have. Lab studies suggest the combination works better than either peptide alone. Microneedling helps both peptides reach the cells they target.
Key Research Areas and Studies
The Head-to-Head Comparison — Matrixyl 3000 vs. Matrixyl
Sederma (2005) — The most significant piece of evidence for Matrixyl 3000's value proposition. N=30 (15 per arm), 8 weeks, measuring crow's feet by profilometry:
Matrixyl 3000: 25% wrinkle reduction. Matrixyl (KTTKS alone): 18% wrinkle reduction. The difference was statistically significant (p<0.05). Both arms showed excellent tolerability. This is the only study that directly compares the dual-peptide complex against its single-peptide predecessor.
Limitation: Manufacturer-sponsored, small sample, short duration, single study.
Efficacy Panels
Sederma placebo-controlled (2002): N=20, 8 weeks. 22% wrinkle reduction vs. 5% placebo. Skin elasticity improved 18% (cutometry).
Sederma multi-center (2004): N=35, 8 weeks. 25% average wrinkle reduction across forehead, crow's feet, and periorbital areas. 80% of subjects showed visible improvement by independent photographic grading. 75% user-perceived significant improvement.
Extended follow-up (2007): N=40, 12 weeks. Progressive benefit: 22% at week 8, 28% at week 12. No plateau. Skin hydration improved progressively. This suggests cumulative collagen synthesis continues with sustained application — which is mechanistically consistent.
Mechanistic Evidence (In Vitro)
Pal-GQPR anti-inflammatory studies (Sederma 2002): Dose-dependent IL-6, TNF-α suppression and MMP-1 inhibition in dermal fibroblasts.
Pal-GHK collagen synthesis (Sederma 2003): Stimulates type I procollagen comparable to GHK-Cu without copper toxicity.
Combination synergy (Sederma 2004): In skin equivalents, the combination showed 35–40% greater collagen accumulation than either peptide alone.
Evidence Limitations — The Transparency Problem
Every clinical and mechanistic study for Matrixyl 3000 originates from Sederma. No independent laboratory has published a peer-reviewed study validating the clinical efficacy, mechanistic synergy, or even the receptor targets. The proprietary peptide ratio further limits reproducibility — products labeled "Matrixyl 3000" could contain different ratios from different suppliers without consumers being able to verify.
This is not evidence of fraud. It is the structural limitation of cosmeceutical evidence: companies fund the research on their own ingredients, and academic incentives for replicating cosmetic ingredient studies are minimal.
PLAIN ENGLISH
Matrixyl 3000 has real clinical data showing it works — 22–28% wrinkle reduction over 8–12 weeks. It beat the original Matrixyl in a direct comparison. The catch: every study was funded by the company that makes it, no independent lab has checked the results, and the exact recipe is a secret. That does not mean it does not work. It means you are trusting the manufacturer's data.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Dual-peptide approach is superior to single peptides"” | Sederma head-to-head: 25% wrinkle reduction (Matrixyl 3000) vs. 18% (single Matrixyl), p<0.05. In vitro: 35–40% greater collagen accumulation vs. either peptide alone. | Supported |
| “"Reduces wrinkle depth by 22–28%"” | Consistent across four Sederma panels over 8–12 weeks. Progressive improvement to 28% at week 12. | Supported |
| “"Builds collagen and protects it simultaneously"” | In vitro confirmed: Pal-GHK stimulates collagen synthesis; Pal-GQPR suppresses MMP-1. Not directly measured in human skin in vivo. | Mixed Evidence |
| “"Results continue to improve beyond 8 weeks"” | Extended follow-up (2007) showed 22% at week 8 → 28% at week 12. No plateau. Consistent with cumulative collagen biology. | Supported |
| “"Anti-inflammatory — reduces inflammaging"” | Pal-GQPR dose-dependently reduces IL-6, TNF-α in vitro. Not directly measured in human skin. "Inflammaging" reduction is inferred. | Mixed Evidence |
| “"Copper-free alternative to GHK-Cu"” | Pal-GHK is structurally GHK without copper. In vitro collagen stimulation comparable to GHK-Cu (Sederma). Eliminates copper-associated irritation risk. | Supported |
| “"Better than retinol"” | No head-to-head vs. retinol exists for Matrixyl 3000 (the retinol comparison was for original Matrixyl). Cannot make this claim. | Unsupported |
| “"Proprietary ratio is optimized"” | Sederma claims optimization, but the ratio is not disclosed. No dose-ratio study published. Consumers cannot verify. | Theoretical |
| “"Microneedling enhances dual-peptide delivery"” | Mechanistically compelling — delivers both peptides to dermis. No Matrixyl 3000-specific microneedling trial. | Theoretical |
| “"Safe for all skin types"” | Excellent tolerability across all studies. Copper-free design reduces irritation risk. 15+ years post-market. | Supported |
| “"Replaces the need for injectable treatments"” | 22–28% wrinkle reduction does not approach injectable botulinum (50–80%), fillers, or laser resurfacing. Complement, not replacement. | Unsupported |
| “"Works on deep wrinkles and jowling"” | Studies measured expression lines and periorbital wrinkles. No evidence for deep nasolabial folds, marionette lines, or jowl correction. | Unsupported |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
What Human Evidence Exists
Matrixyl 3000 has approximately 125 subjects across four manufacturer-sponsored clinical panels, including one head-to-head comparison against single-peptide Matrixyl. The evidence consistently shows 22–28% wrinkle reduction over 8–12 weeks with excellent tolerability. The extended follow-up study (12 weeks) demonstrated progressive improvement without plateau.
What Human Evidence Is Missing
No independently funded study has been published. No study has measured dermal collagen content directly (all endpoints are cosmetic — wrinkle depth, elasticity, hydration). No study has compared Matrixyl 3000 to retinol. No microneedling-enhanced delivery study exists. The proprietary peptide ratio has never been validated by an independent formulation chemist.
What Would Change the Verdict
Independent replication of the head-to-head Matrixyl comparison would substantially strengthen the evidence. A skin biopsy study demonstrating increased collagen density and reduced MMP-1 activity would validate the dual-mechanism claim. A retinol head-to-head (like Robinson 2005 for original Matrixyl) would position Matrixyl 3000 definitively.
PLAIN ENGLISH
About 125 people have been tested with Matrixyl 3000 in clinical studies. The results are consistent: 22–28% wrinkle reduction over 8–12 weeks, and it beats the original Matrixyl in the only comparison. What is missing: independent verification and direct proof that it actually increases collagen in living skin.
Safety, Risks, and Limitations
Tolerability Profile
Matrixyl 3000 has an excellent safety record. Copper-free formulation — a deliberate design choice — eliminates the irritation and oxidative stress risk associated with copper-containing GHK-Cu formulations.
Dermal irritation: None across all clinical trials. Excellent for sensitive skin types.
Systemic absorption: Negligible. Both palmitoylated peptides show minimal transdermal flux beyond the dermis.
Phototoxicity: None. Safe for daytime use with sunscreen.
Allergic reactions: Rare (<0.1%). Contact dermatitis when reported is attributable to formulation co-ingredients.
Limitations
Proprietary ratio. The exact ratio of Pal-GHK to Pal-GQPR is not disclosed. Different manufacturers may use different ratios under the same ingredient name, and consumers have no way to evaluate this variable.
Effect ceiling. 22–28% wrinkle reduction is the documented range. Users expecting dramatic results will be disappointed.
Slow onset. 8–12 weeks for measurable results. Faster than some collagen-building approaches but slower than neuromuscular inhibitors like Argireline (2–4 weeks).
Continuous use required. Reversible upon discontinuation.
Legal and Regulatory Status
FDA Classification
Both components (Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7) are accepted cosmetic ingredients. The proprietary blend does not require ratio disclosure under cosmetic labeling regulations. Marketing claims must remain cosmetic, not therapeutic.
WADA Status
Not prohibited. Topical cosmetic peptides with negligible systemic absorption.
International Status
Accepted in the EU (CosIng), China, Japan, Australia, and all major cosmetics markets. No prescription required.
Research Protocols and Formulation Considerations
Formulation Variables
Concentration: Proprietary. Sederma's recommended usage level is not publicly disclosed, though clinical panels used concentrations in the typical cosmeceutical active range.
Vehicle: Serums recommended for optimal delivery of palmitoylated peptides.
Storage: Room temperature, away from direct sunlight. 2–8°C (35–46°F) extends shelf life.
Delivery Method Comparison
| Method | Penetration | Evidence | Best For |
|---|---|---|---|
| Topical cream/serum | Moderate — dual palmitoyl chains help | Sederma panels (standard method) | Daily maintenance, gradual dual-pathway benefit |
| Microneedling-enhanced | High — delivers both peptides directly to dermis | Mechanistically ideal; no trial | Maximizing both fibroblast activation and anti-inflammatory benefit |
| SC injectable | Not applicable | Not used as injectable | — |
Dosing in Published Research
Published Protocol Parameters
Application frequency: Twice daily (morning and evening) in clinical studies Duration to measurable effect: 8 weeks (progressive improvement through 12 weeks) Application sites: Periorbital, forehead, full face
Microneedling Protocol
1. Microneedle target areas with 0.25–0.5 mm device 2. Apply Matrixyl 3000 serum immediately (within 5 minutes) 3. Allow 10–15 minutes for absorption 4. Repeat microneedling every 2–4 weeks 5. See our [Topical Peptides guide](/guides/topical-peptides/#microneedling) for full protocol
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
The following table summarizes community-reported dosing practices for Matrixyl 3000. These are not clinical recommendations. No controlled trial data supports these protocols.
| Route | Community Use | Evidence | Dose (Range) | Key Risks |
|---|---|---|---|---|
| Topical serum (daily) | Most common — twice-daily application | Supported by Sederma panels | Proprietary concentration, 2x daily | Minimal — excellent tolerability |
| Microneedling + serum | Growing — enhanced delivery to dermis | Mechanistically sound; no trial | Serum post-needling, every 2–4 weeks | Infection risk from needling (not compound-specific) |
| Combination with Argireline | Very common — complementary mechanisms | Theoretically rational; no combination trial | Various | No known interaction risks |
| Combination with retinol | Common in premium routines | Different pathways; no direct study | Various | Retinol irritation risk (not Matrixyl 3000) |
PLAIN ENGLISH
Most people apply Matrixyl 3000 as a daily serum. The smart approach is combining it with microneedling every few weeks to get both peptides deeper into the skin. Many users also layer it with Argireline (for expression lines) — different mechanisms that work on different problems.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Matrixyl 3000 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Matrixyl 3000 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Related Compounds: How Matrixyl 3000 Compares
Matrixyl 3000 belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Skin & Cosmetic cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Mechanism | Primary Use Case | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Argireline | Acetyl Hexapeptide-3 (Ac-EEMQRR-NH2); 889 Da | Tier 3 — Limited Human Data | Reasonable Bet | SNAP-25 mimetic → inhibits SNARE complex assembly → reduces ACh release at NMJ; topical 'botox-like' effect without cleaving SNARE | Expression wrinkle reduction; forehead and crow's feet | ~200 in clinical studies; 10–30% wrinkle reduction in 4 weeks | Not approved as drug (cosmetic ingredient; INCI listed) | Not prohibited | Penetration to dermal-epidermal junction unproven; effect magnitude far less than injectable botulinum toxin; manufacturer-sponsored studies |
| Matrixyl | Palmitoyl Pentapeptide-4 (Pal-KTTKS); 802 Da | Tier 3 — Limited Human Data | Reasonable Bet | Matrikine signaling — KTTKS collagen fragment stimulates fibroblast collagen I/III/IV synthesis + fibronectin + glycosaminoglycans; palmitoyl enhances penetration | Wrinkle reduction; collagen stimulation; skin texture improvement | ~150 in clinical studies; comparable to retinol in head-to-head | Not approved as drug (cosmetic ingredient) | Not prohibited | Primarily manufacturer-sponsored studies; independent validation limited; comparisons to retinol, not vehicle alone |
| Matrixyl 3000 | Palmitoyl Tetrapeptide-7 + Palmitoyl Tripeptide-1 (Pal-GQPR + Pal-GHK); blend | Tier 3 — Limited Human Data | Reasonable Bet | Dual action: Pal-GHK (matrikine collagen stimulation) + Pal-GQPR (IL-6 suppression + MMP-1 inhibition); build collagen while preventing degradation | Wrinkle reduction; anti-aging; skin firmness | ~120 in clinical studies; 22–28% wrinkle reduction | Not approved as drug (cosmetic ingredient) | Not prohibited | Proprietary blend (exact ratios undisclosed); primarily manufacturer data; less independent validation than Matrixyl |
| SNAP-8 | Acetyl Octapeptide-3 (Ac-EEMQRRAD-NH2); 1,075 Da | Tier 4 — Preclinical Only | Eyes Open | Extended SNAP-25 mimetic (8 vs 6 AA); claimed greater SNARE inhibition than Argireline; same mechanism, additional binding contacts | Expression wrinkle reduction (claimed superior to Argireline) | None — zero peer-reviewed human studies | Not approved as drug (cosmetic ingredient) | Not prohibited | Zero published human efficacy data; larger MW may worsen skin penetration; marketed as 'superior' without human validation |
| Leuphasyl | Pentapeptide-18 (Tyr-D-Ala-Gly-Phe-Leu); 569 Da; enkephalin analog | Tier 4 — Preclinical Only | Thin Ice | Mu-opioid receptor agonist on sensory nerve terminals → reduces ACh release via presynaptic inhibition; different upstream mechanism than Argireline | Expression wrinkle reduction (Argireline synergist) | None — zero published human studies | Not approved as drug (cosmetic ingredient) | Not prohibited | Opioid receptor agonist topically — penetration to dermal nerve terminals undemonstrated; no independent data; marketed only as Argireline booster |
| Palmitoyl Tripeptide-1 | Pal-GHK (Biopeptide-CL); 578 Da | Tier 3 — Limited Human Data | Reasonable Bet | GHK matrikine signaling → fibroblast collagen synthesis + ECM remodeling; palmitoyl enhances skin penetration; GHK-Cu without the copper | Collagen stimulation; anti-aging; wound healing signal | ~80 in clinical studies (mostly in Matrixyl 3000 combo) | Not approved as drug (cosmetic ingredient) | Not prohibited | Usually studied in combination (Matrixyl 3000); hard to isolate individual contribution; GHK-Cu has more independent research |
| Palmitoyl Tetrapeptide-7 | Pal-GQPR; 687 Da; IgG fragment mimic | Tier 3 — Limited Human Data | Eyes Open | Anti-inflammatory: reduces IL-6 keratinocyte secretion + suppresses UVB inflammation + inhibits MMP-1 collagenase expression | Anti-inflammatory; collagen preservation; UVB damage reduction | ~60 (only as part of Matrixyl 3000 combination) | Not approved as drug (cosmetic ingredient) | Not prohibited | Never studied independently of Pal-GHK partner; clinical contribution unknown; anti-inflammatory mechanism plausible but unvalidated alone |
| Syn-Ake | Dipeptide Diaminobutyroyl Benzylamide Diacetate; ~390 Da | Tier 4 — Preclinical Only | Eyes Open | Claimed nAChR antagonism mimicking waglerin-1 (temple viper venom) → muscle relaxation → reduced expression lines | Expression wrinkle reduction ('snake venom–inspired') | 1 unpublished manufacturer panel study (~45 subjects) | Not approved as drug (cosmetic ingredient) | Not prohibited | Marketing narrative ('snake venom') far exceeds evidence; structural resemblance to waglerin-1 is minimal; zero peer-reviewed data; nAChR blockade unverified |
| Acetyl Tetrapeptide-5 | Ac-β-Ala-His-Ser-His (Eyeseryl); ~493 Da | Tier 4 — Preclinical Only | Eyes Open | Anti-edema: reduces vascular permeability + fluid accumulation; anti-glycation of capillary walls; targets periorbital puffiness | Under-eye puffiness (de-puffing); periorbital application | None — manufacturer panel data only (unpublished) | Not approved as drug (cosmetic ingredient) | Not prohibited | No peer-reviewed evidence; mechanism (anti-edema via glycation inhibition) is speculative; marketed for very specific niche (eye bags) |
| Palmitoyl Hexapeptide-12 | Palmitoyl Hexapeptide-12; ~921 Da | Tier 4 — Preclinical Only | Thin Ice | Proposed collagen + hyaluronic acid synthesis stimulation; adhesion molecule expression for dermal-epidermal junction integrity | Anti-aging; collagen stimulation (unvalidated) | None — zero evidence of any kind | Not approved as drug (cosmetic ingredient) | Not prohibited | Zero peer-reviewed data; no mechanism validation; no manufacturer claims with detail; exists on ingredient lists by category association only |
| AHK-Cu | Ala-His-Lys-Cu²⁺; ~428 Da; copper tripeptide | Tier 4 — Preclinical Only | Thin Ice | Copper tripeptide signaling → proposed collagen/elastin synthesis via LOX activation; GHK-Cu analog with different N-terminal residue | Hair growth; wound healing; collagen stimulation | None — zero published human studies for AHK-Cu specifically | Not approved as drug (cosmetic ingredient) | Not prohibited | Evidence borrowed from GHK-Cu; no independent validation for AHK specifically; alanine substitution impact unknown; most marketing cites GHK-Cu data |
| Tripeptide-29 | Gly-Pro-Hyp (collagen tripeptide); ~285 Da | Tier 3 — Limited Human Data | Reasonable Bet | Matrikine signaling — most abundant collagen repeat; stimulates fibroblast collagen I synthesis + anti-glycation (AGE reduction) + MMP inhibition | Collagen stimulation; anti-aging; anti-glycation; skin hydration | ~202 across 4 studies (1 topical pilot N=22; 3 oral RCTs N=32–84) | Not approved as drug (cosmetic/GRAS ingredient) | Not prohibited | Topical study uncontrolled; oral RCTs test multi-component hydrolysates (3–15% Gly-Pro-Hyp), not isolated tripeptide; low oral bioavailability (4.4%) |
Frequently Asked Questions
Summary of Key Findings
Matrixyl 3000 is a rationally designed dual-peptide complex that addresses aging skin from two complementary angles: Pal-GHK stimulates fibroblast collagen synthesis (anabolic), while Pal-GQPR suppresses MMP-1 and inflammatory cytokines that destroy collagen (catabolic inhibition). In manufacturer-sponsored clinical studies totaling ~125 subjects, the combination achieves 22–28% wrinkle reduction over 8–12 weeks — modestly superior to single-peptide Matrixyl (18–20%) in direct comparison.
The dual-pathway logic is sound and supported by in vitro synergy data showing 35–40% greater collagen accumulation vs. either peptide alone. Safety is excellent: 15+ years of post-market use, copper-free design eliminates GHK-Cu-associated irritation, and no adverse events have been reported.
Limitations include entirely manufacturer-sponsored evidence, undisclosed proprietary peptide ratio, and cosmetic endpoints only (no direct collagen measurement in human skin). The progressive improvement from week 8 to week 12 without plateau is mechanistically consistent with cumulative collagen synthesis.
Microneedling is the highest-confidence delivery method for Matrixyl 3000, delivering both peptides directly to dermal targets. Topical application with palmitoyl-enhanced penetration is the standard approach.
PLAIN ENGLISH
Matrixyl 3000 combines a collagen-builder and a collagen-protector in one product. Clinical studies show it reduces wrinkles by 22–28% over two to three months — modestly better than the original Matrixyl. The dual approach makes scientific sense. All the evidence comes from the company that sells it, and the exact recipe is secret. Microneedling helps both peptides reach where they need to go.
Verdict Recapitulation
Matrixyl 3000 earns Tier 3 because human clinical data demonstrates consistent efficacy with head-to-head superiority over single-peptide alternatives. It earns "Reasonable Bet" because the dual-pathway mechanism is sound, the effect is real and modestly superior, and the safety is excellent — but the evidence base is entirely manufacturer-sponsored and the proprietary ratio limits transparency.
For readers considering Matrixyl 3000, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Matrixyl 3000
Further Reading and Resources
If you want to go deeper on Matrixyl 3000, the evidence landscape for skin & cosmetic peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Skin & Cosmetic Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Matrixyl 3000 — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Lintner K, Peschard O. "Biologically active peptides: from a laboratory bench curiosity to a functional skin care product." International Journal of Cosmetic Science. 2000;22(3):207–218. PMID 18503476
- Pickart L, Vasquez-Soltero JM, Margolina A. "GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration." BioMed Research International. 2015;2015:648108. PMID 22585060
- Robinson LR, Fitzgerald NC, Phua DG, et al. "Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin." International Journal of Cosmetic Science. 2005;27(3):155–160. PMID 15675024
- Katayama T, Deng SB, Friend DS, et al. "Fetal skin fibroblasts and skin-equivalent tissue produced in vitro." Journal of Investigative Dermatology. 1993;100(4):356–363. PMID 8440894
- Gorouhi F, Maibach HI. "Role of topical peptides in preventing or treating aged skin." International Journal of Cosmetic Science. 2009;31(5):327–345. PMID 19570099
- Pai VV, Bhandari P, Shukla P. "Topical peptides as cosmeceuticals." Indian Journal of Dermatology, Venereology and Leprology. 2017;83(1):9–18. PMID 27549869
- Reddy BY, Jow T, Hantash BM. "Bioactive oligopeptides in dermatology: Part I." Experimental Dermatology. 2012;21(8):563–568. PMID 22775992
- Sederma (Lubrizol). "Matrixyl 3000 — Clinical Efficacy Reports." Cosmetic industry white papers, 2002–2007. (Manufacturer data; multiple panels.)
- Sederma (Lubrizol). "Comparative Efficacy: Matrixyl 3000 vs. Matrixyl." Internal study, 2005. (Head-to-head comparison; not peer-reviewed.)
- Abu Samah NH, Heard CM. "Topically applied KTTKS: a review." International Journal of Cosmetic Science. 2011;33(6):483–490. PMID 21564138
- Zhang S, Duan E. "Fighting against Skin Aging: The Way from Bench to Bedside." Cell Transplantation. 2018;27(5):729–738. PMID 29692196
- Schagen SK. "Topical Peptide Treatments with Effective Anti-Aging Results." Cosmetics. 2017;4(2):16
DISCLAIMER
Matrixyl 3000 is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 08, 2026. Next scheduled review: October 05, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.